



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Increased levels of phosphoinositides cause neurodegeneration in a *Drosophila* model of amyotrophic lateral sclerosis

Citation for published version:

Forrest, S, Chai, A, Sanhueza, M, Marescotti, M, Parry, K, Georgiev, A, Sahota, V, Mendez-Castro, R & Pennetta, G 2013, 'Increased levels of phosphoinositides cause neurodegeneration in a *Drosophila* model of amyotrophic lateral sclerosis' *Human Molecular Genetics*, vol 22, no. 13, pp. 2689-704. DOI: 10.1093/hmg/ddt118

Digital Object Identifier (DOI):

[10.1093/hmg/ddt118](https://doi.org/10.1093/hmg/ddt118)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

Human Molecular Genetics

Publisher Rights Statement:

© The Author 2013. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by-nc/3.0/>), which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permission@oup.com

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Increased levels of phosphoinositides cause neurodegeneration in a *Drosophila* model of amyotrophic lateral sclerosis

Stuart Forrest^{1,2}, Andrea Chai^{1,2,†}, Mario Sanhueza^{1,2}, Manuela Marescotti^{1,2}, Katherine Parry^{1,2}, Atanas Georgiev^{1,2}, Virender Sahota^{1,2}, Raquel Mendez-Castro^{1,2} and Giuseppa Pennetta^{1,2,*}

¹Center for Integrative Physiology and ²Euan MacDonald Center for Motor Neuron Disease Research, School of Biomedical Sciences, University of Edinburgh, Edinburgh, UK

Received November 26, 2012; Revised and Accepted March 7, 2013

The Vesicle-associated membrane protein (VAMP)-Associated Protein B (VAPB) is the causative gene of amyotrophic lateral sclerosis 8 (ALS8) in humans. Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by selective death of motor neurons leading to spasticity, muscle atrophy and paralysis. VAP proteins have been implicated in various cellular processes, including intercellular signalling, synaptic remodelling, lipid transport and membrane trafficking and yet, the molecular mechanisms underlying ALS8 pathogenesis remain poorly understood. We identified the conserved phosphoinositide phosphatase Sac1 as a *Drosophila* VAP (DVAP)-binding partner and showed that DVAP is required to maintain normal levels of phosphoinositides. Downregulating either *Sac1* or *DVAP* disrupts axonal transport, synaptic growth, synaptic microtubule integrity and the localization of several postsynaptic components. Expression of the disease-causing allele (*DVAP-P58S*) in a fly model for ALS8 induces neurodegeneration, elicits synaptic defects similar to those of *DVAP* or *Sac1* downregulation and increases phosphoinositide levels. Consistent with a role for Sac1-mediated increase of phosphoinositide levels in ALS8 pathogenesis, we found that *Sac1* downregulation induces neurodegeneration in a dosage-dependent manner. In addition, we report that Sac1 is sequestered into the *DVAP-P58S*-induced aggregates and that reducing phosphoinositide levels rescues the neurodegeneration and suppresses the synaptic phenotypes associated with *DVAP-P58S* transgenic expression. These data underscore the importance of DVAP–Sac1 interaction in controlling phosphoinositide metabolism and provide mechanistic evidence for a crucial role of phosphoinositide levels in VAP-induced ALS.

INTRODUCTION

Amyotrophic lateral sclerosis (ALS) is a progressive, degenerative disorder characterized by the selective loss of motor neurons in the brain and spinal cord leading to paralysis, muscle atrophy and eventually, death (1). Two missense mutations in the gene encoding the human Vesicle-associated membrane protein (VAMP)-Associated Protein B (hVAPB) causes a range of dominantly inherited motor neuron diseases including ALS8 (2,3). VAP family proteins are characterized by an N-terminal major sperm protein (MSP) domain, a coiled-coil

(CC) motif and a transmembrane (TM)-spanning region. They are implicated in several biological processes, including regulation of lipid transport, endoplasmic reticulum (ER) morphology and membrane trafficking (4). *Drosophila Vap-33-I* (hereafter, *DVAP*) regulates synaptic structure, synaptic microtubule (MT) stability and the composition of postsynaptic glutamate receptors (5,6). MSP domains in DVAP are cleaved and secreted into the extracellular space where they bind Ephrin receptors (7). MSPs also bind postsynaptic Roundabout and Lar-like receptors to control muscle mitochondria morphology, localization and function (8).

*To whom correspondence should be addressed at: Centre for Integrative Physiology, School of Biomedical Sciences, Hugh Robson Building, George Square, EH8 9XD, Edinburgh, UK. Tel: +44 1316513201; Fax: +44 1316511691; Email: g.pennetta@ed.ac.uk

†Present address: Department of Human and Molecular Genetics, Baylor College of Medicine, Houston, TX, USA.

Transgenic expression of the disease-linked alleles (*DVAP-P58S* and *DVAP-T48I*) in the larval motor system recapitulates major hallmarks of the human disease, including aggregate formation, locomotion defects and chaperone upregulation (3,6,9). Several studies have also implicated the ALS mutant allele in abnormal unfolded protein response (UPR) (3,10–13) and in the disruption of the anterograde axonal transport of mitochondria (14). However, it is unclear how these diverse VAP functions are achieved and which mechanisms underlie the disease pathogenesis in humans. One way to address these questions is to search for DVAP-interacting proteins. We identified Sac1 (Suppressor of Actin 1), an evolutionarily conserved phosphoinositide phosphatase, as a DVAP-binding protein. Phosphoinositides are low-abundance lipids that localize to the membrane–cytoplasm interface and function by binding various effector proteins. The inositol group can be reversibly phosphorylated at the 3', 4' and 5' positions to generate seven possible phosphoinositide derivatives, each with a specific intracellular dynamic distribution (15). Sac1 predominantly dephosphorylates PtdIns4P pools, although PtdIns3P and PtdIns(3,5)P₂ can also function as substrates (16). In yeast, Sac1 has been linked to several processes, including actin organization, vacuole morphology and sphingomyelin synthesis (17,18). *Drosophila* Sac1 mutants die as embryos and exhibit defects in dorsal closure and axonal pathfinding (19,20). Mouse lines deficient for *Sac1* are cell lethal, whereas *Sac1* downregulation in mammalian cell cultures results in disorganization of Golgi membranes and mitotic spindles (21). Interestingly, SAC3 (also known as FIG4), another member of the Sac phosphatase family, is mutated in familial and sporadic cases of ALS (22). Inactivation of *SAC3* in mice also results in extensive degeneration and neuronal vacuolization in the brain, most relevantly in the motor cortex (23). We identified Sac1 and DVAP as binding partners and show that DVAP is required to maintain normal levels of PtdIns4P. Loss of either Sac1 or DVAP function disrupts axonal transport, MT stability, synaptic growth and the localization of a number of postsynaptic markers. We also show that the disease-causing mutation (*DVAP-P58S*) induces neurodegeneration and displays synaptic phenotypes similar to those of either Sac1 or DVAP loss-of-function, including an increase in PtdIns4P levels. Importantly, reducing PtdIns4P levels rescues the neurodegeneration associated with *DVAP-P58S* and suppresses the synaptic phenotypes associated with *DVAP-P58S* and *DVAP* loss-of-function alleles. Consistent with these observations, Sac1 is sequestered into *DVAP-P58S*-mediated aggregates and downregulation of *Sac1* in neurons induces increased PtdIns4P levels and degeneration. These data highlight the crucial role of *DVAP* and *Sac1* in regulating phosphoinositides and support a causative role for PtdIns4P levels in ALS8 pathogenesis.

RESULTS

DVAP physically interacts with Sac1

A previous yeast two-hybrid screen for large-scale mapping of protein–protein interactions in *Drosophila* identified Sac1 as a DVAP-interacting protein (24). We confirmed this by yeast

two-hybrid binary interaction and co-immunoprecipitation assays. A yeast two-hybrid analysis to detect a binary interaction between DVAP and Sac1 showed that these proteins can bind each other and that both the disease-causing alleles *DVAP-P58S* and *DVAP-T48I* retained their ability to bind Sac1 (Fig. 1A). For the co-immunoprecipitation assays, Myc-tagged *Sac1* and Flag-tagged *DVAP* constructs were transfected in COS7 cells. In cell extracts expressing both Myc-tagged *Sac1* and Flag-tagged *DVAP*, Flag-DVAP was clearly co-immunoprecipitated with Myc-Sac1 by the anti-Myc antibody. In agreement with the yeast two-hybrid data, Flag-DVAP-P58S was also significantly co-immunoprecipitated with Myc-Sac1. As a control, little co-immunoprecipitation was observed using cell extracts expressing either Flag-DVAP or Flag-DVAP-P58S but not Myc-Sac1 (Fig. 1B).

To further extend this analysis, we mapped the interaction domains on both proteins by yeast two-hybrid assay. Sac1 contains a conserved phosphoinositide–phosphatase module termed the Sac domain, comprising seven highly conserved motifs, including the catalytic domain. It also contains an N-terminal leucine zipper motif and two C-terminal putative TM domains, TM1 and TM2. We found that whereas TM2 was dispensable for the binding activity of Sac1, truncation of the first 18 amino acids encompassing the β 1 helix effectively abolished Sac1 binding to DVAP (Fig. 1C). DVAP also exhibits conserved structural domains, including the MSP domain, a CC motif and a TM domain. Surprisingly, we found that the MSP domain was dispensable for the interaction, whereas removal of the C-terminal TM domain abolished the ability of DVAP to physically interact with Sac1 (Fig. 1D). Collectively, our data indicate that DVAP binds Sac1 via its TM and that a Sac1 fragment of 546 amino acids lacking the most C-terminal TM is necessary to bind DVAP. These data also show that ALS8-causing mutations do not affect the ability of DVAP to bind Sac1.

Presynaptic Sac1 is required for synaptic morphology, MT organization and axonal transport

Since DVAP and Sac1 physically interact, we asked whether mutations in Sac1 could affect the same biological processes as those affected by mutations in DVAP. DVAP loss-of-function mutations lead to a synaptic phenotype at the larval neuromuscular junction (NMJ) characterized by a reduction in the number of boutons and an increase in their size (5). Strong hypomorphic mutations in Sac1 cause embryonic lethality due to an early requirement of the gene during development (19). We therefore undertook a transgenic RNA interference (RNAi) approach to reduce Sac1 protein level during postembryonic development from the presynaptic side. We selectively expressed *Sac1RNAi* in neurons, using the *UAS-Gal4* system and the neuronal-specific driver *elav-Gal4*. Staining with anti-HRP antibodies that label and allow for visualization of synaptic terminals showed that reducing Sac1 expression in presynaptic cells (*elav;Sac1RNAi*) led to a decrease in bouton number (181 ± 3.9 versus 280 ± 4.6 in controls) and a concomitant increase in their size (Fig. 2A and C and Supplementary Material, Fig. S1A and B). To dissect the cell-specific role of *DVAP*, we downregulated *DVAP* expression in presynaptic cells, using *DVAPRNAi* lines and the *elav-Gal4* driver.




Figure 1. Sac1 interacts with both DVAP and DVAP-P58S. (A) Sac1 interaction with DVAP and DVAP-P58S by yeast two-hybrid assay. p53/T-Ag interaction is the positive control and the lack of interaction between T-Ag and Lamin (LAM) is used as a negative control. Sac1 interacts with DVAP as well as with DVAP-P58S and DVAP-T48I. AD, Gal4 activation domain. DB, Gal4 DNA-binding domain. (B) Co-immunoprecipitation of Myc-Sac1 and Flag-DVAP or Flag-DVAP-P58S from cell lysates transfected with the indicated plasmids. Immunoprecipitates were collected on anti-Myc Sepharose beads. Input (I), immunoprecipitated complexes indicated as pellet (P) and the unbound fractions indicated as supernatant (S) were analysed by western blots with antibodies to DVAP or Myc. (C) DVAP interaction with Sac1-truncated proteins. LZ, leucine zipper; CD, catalytic domain; TM1, TM2, transmembrane domains 1, 2. On the right column, interactions (Int) are indicated by plus signs and lack of interaction by minus signs. In (D), Sac1 interaction with DVAP-truncated proteins is reported. MSP, major sperm protein; CC, coiled coil; TM, transmembrane domains. Interactions (Int) are indicated by plus signs and lack of interaction is indicated by minus signs. The CC domain (amino acids 184–227) and the TM domain (amino acids 250–266) were deleted from DVAP.

Presynaptic knockdown of *DVAP* (*elav;DVAPRNAi^{GD3990}*) induced a synaptic morphological phenotype similar to those of *DVAP* null mutations (5) and presynaptic *Sac1RNAi* expression (Fig. 2A–C and Supplementary Material, Fig. S1A and B).

The presynaptic MT cytoskeleton, as visualized by staining with antibodies specific for the MAP1B-like protein Futsch, is severely perturbed in *DVAP* mutant NMJs (5). We tested whether *Sac1* or *DVAP* downregulation in neurons affected MT stability at the NMJ. In control NMJs, MTs run mainly as a filament of Futsch staining across the nerve terminal branches (Fig. 2A). Occasionally, Futsch staining appears punctuate or splayed into a number of thinner filaments filling up the entire volume of the boutons. These two forms of staining, i.e. ‘punctuate and splayed’ have been described as two variant forms of disorganized MTs found in mutants affecting synaptic architecture (25,26). At both *elav;Sac1RNAi* and *elav;DVAPRNAi^{GD3990}* NMJs, there was an increase in the number of boutons showing MT disorganization. Although in controls the percentage of boutons exhibiting the ‘filled’ or ‘diffuse’ pattern of Futsch staining was only 35.7 ± 1.4 , the number of boutons with the same pattern in *elav;Sac1RNAi* and *elav;DVAPRNAi^{GD3990}* NMJs was 58.3 ± 1.7 and $70.5 \pm 2.4\%$, respectively (Fig. 2B and C; Supplementary Material, Fig. S1C).

Although the axonal MT cytoskeleton had no obvious morphological defects (data not shown), we observed abnormalities in the distribution of proteins and synaptic vesicles along the nerves. At control NMJs, Bruchpilot (Brp), an essential component of the synaptic active zones (27), was barely

detectable along the nerves (Fig. 2D). Conversely, both *elav;DVAPRNAi^{GD3990}* and *elav;Sac1RNAi* mutants exhibited massive accumulation of Brp aggregates along the axons (Fig. 2E and F, Supplementary Material, Fig. S1D). Similar aggregates were observed using antibodies specific for the vesicle-associated cysteine string protein (data not shown). Hence, these results indicate that DVAP and Sac1 exhibit functional similarity and control several aspects of NMJ physiology, including synaptic structure, axonal transport and MT organization.

Postsynaptic downregulation of either *Sac1* or *DVAP* affects synaptic morphology and the distribution of several synaptic markers

To assess the postsynaptic function of Sac1, we focused on two phosphoinositide-dependent proteins, adducin and β -spectrin, both with established NMJ function and involvement in ALS pathogenesis or neurodegeneration (28–31).

The muscle-specific driver *BG57-Gal4* was used to express either *Sac1RNAi* or *DVAPRNAi* transgene postsynaptically. In controls, synaptic boutons had a rounded to oval appearance and were separated from each other by a well-defined neural process (Fig. 3A). Adducin, a predominantly postsynaptic marker, colocalized with and surrounded the presynaptic membrane defined by HRP staining (Fig. 3A). In both *BG57/DVAPRNAi^{GD3990}* and *BG57;Sac1RNAi* mutants, a complex phenotype affecting both the pre- and postsynaptic compartments was observed. The most striking effect was an aberrant synaptic




Figure 2. Presynaptic *Sac1* and DVAP are required for synaptic morphology, MT integrity and axonal transport. (A–C) Representative confocal images of muscle 12 synapses stained for both HRP and Futsch in *elav-Gal4/+* controls (A), *elav;DVAPRNAi^{GD3990}* larvae (B) and *elav;Sac1RNAi* transgenic mutants (C). *elav;DVAPRNAi^{GD3990}* and *elav;Sac1RNAi* NMJs exhibit a significant increase in the number of boutons with splayed (arrow) and lack or punctuate (arrow-head) Futsch staining. (D–F) Representative confocal images of nerves stained for both HRP and Bruchpilot (Brp) in controls (D), *elav;DVAPRNAi^{GD3990}* (E) and *elav;Sac1RNAi* transgenic larvae (F). Bar = 10 μ m.

morphology, although the number of boutons remained nearly normal. Boutons were larger and exhibited a highly irregular shape with a number of spike-like protrusions emerging from their contours. Remarkably, a mismatched apposition between the presynaptic membrane visualized by the HRP staining and the postsynaptic marker adducin was observed in mutants when compared with controls (Fig. 3B and C). At the postsynaptic compartment, adducin no longer tightly associated with the presynaptic boutons to entirely circumscribe the presynaptic membrane as in controls but it appeared confined to specific subregions of the membrane and absent or diffused in others (Fig. 3B and C). Similar phenotypes were observed for β -spectrin (Supplementary Material, Fig. S2A–C). Moreover, the postsynaptic localization of Discs-Large (DLG), the *Drosophila* homologue of the mammalian PSD-95, has been shown to depend on both adducin and β -spectrin (32,33). As expected, in both *DVAPRNAi^{GD3990}* and *Sac1RNAi* muscles, DLG was not surrounding the perimeter of the boutons but appeared rather disorganized and diffused (Supplementary Material, Fig. S2D–F). A high degree of heterogeneity among the different phenotypic classes was observed; however, the most abnormal bouton branches were those with the most aberrant organization in the distribution and localization of the adducin and β -spectrin postsynaptic markers. This is in agreement with previous data reporting that disruption of the

actin–spectrin postsynaptic cytoskeleton can affect the shape and the appearance of presynaptic boutons (34). DVAP null alleles do not exhibit the morphological phenotype associated with postsynaptic downregulation of DVAP. A possible cause for this apparent discrepancy could be the non-cell autonomous effect of DVAP (7), as in this case phenotypic outcomes do not simply depend on the genotype of a mutant cell but may be also affected by the genotype of neighbouring cells.

It is well known that off-target activity can complicate the interpretation of phenotypic effects in gene silencing experiments by RNAi. To test the specificity of *Sac1* knock-down by RNAi, we showed that expression of the *Sac1RNAi* construct in larval brains resulted in an almost complete depletion of *Sac1* RNA (Supplementary Material, Fig. S3A). To exclude the possibility of off-target effects, we performed a phenotypic analysis of larvae expressing a *Sac1* transgenic line (Δ *Sac1*) in which the –RTNCIDCLDRTN– catalytic site has been removed. Expression of the Δ *Sac1* transgenic line in a wild-type background should have a dominant negative effect and should exhibit mutant phenotypes similar to those of a *Sac1* loss-of-function allele. As expected, targeting the expression of Δ *Sac1* allele either pre- or postsynaptically led to a phenotype similar to those associated with *Sac1* downregulation by *Sac1RNAi* (Supplementary Material, Fig. S3B–G).




Figure 3. Postsynaptic downregulation of either DVAP or *Sac1* induces changes in bouton morphology and adducin disorganization. (A–C) Representative confocal images of larval NMJs stained for HRP and adducin in *BG57-Gal4/+* controls (A), *BG57/DVAPRNAi^{GD3990}* transgenic mutants (B) and *BG57;Sac1RNAi* transgenic mutants (C). Asterisks indicate big and irregular boutons; arrowheads point to spikes; triangles show mismatched apposition of pre- and post-synaptic components and arrows indicate diffused and missing adducin staining. Bar = 10 μ m.

For *DVAP*, two *RNAi* lines are available: *DVAPRNAi^{GD3990}* from the VDRC (Vienna *Drosophila* RNAi Center) collection and *DVAPRNAi^{JF02621}* from the TRiP collection. These lines were generated using constructs containing inverted repeats that target different, non-overlapping sequences within *DVAP* (see Materials and Methods for details). The *DVAPRNAi^{GD3990}* line effectively knocks down *DVAP* expression in salivary glands and brains from progeny of *elav-Gal4* flies crossed to *DVAPRNAi^{GD3990}* flies (Supplementary Material, Fig. S4). A similar decrease in DVAP levels was associated with transgenic expression of *DVAPRNAi^{JF02621}* in the same tissues (data not shown). In addition, either pre- or postsynaptic expression of *DVAPRNAi^{JF02621}* induced mutant phenotypes reminiscent of those associated with *DVAPRNAi^{GD3990}* transgenic expression (Supplementary Material, Fig. S5). Together, these data indicate that for both DVAP and *Sac1*, gene knockdown by RNAi was specific and exclusively affected the intended genes.

Studies in *Drosophila* have suggested that *DVAP-P58S* could act as a dominant negative allele by sequestering wild-type DVAP into aggregates and depleting it from its normal localization (6,9). If this holds true for the DVAP–*Sac1* interaction as well, then *DVAP-P58S* flies should exhibit mutant phenotypes similar to both *DVAP* and *Sac1* downregulation. Indeed, the mutant phenotypes associated with both pre- and postsynaptic expression of *DVAP-P58S* (Supplementary Material, Figs S1, S6 and S7) were highly similar to those of *DVAPRNAi* and *Sac1RNAi* in the same tissues, thus confirming the proposed genetic effect of the *DVAP-P58S* allele.

The phenotypes associated with synaptic downregulation of *Sac1* are highly reminiscent of those of *DVAPRNAi* mutants, suggesting that *DVAP* and *Sac1* function in the same pathway. To assess additive effects, we focused on the easily quantifiable presynaptic morphology phenotype. Both *elav;Sac1RNAi* and *elav;DVAPRNAi^{GD3990}* exhibited a reduction in bouton

number with a concomitant increase in their size. We noticed that *elav;DVAPRNAi^{GD3990};Sac1RNAi* double mutants did not show any further severity in the phenotype when compared with either single mutant alone (Supplementary Material, Fig. S8). Taken together, these data indicate that *Sac1* and *DVAP* do indeed function in a common pathway.

Sac1 colocalizes with DVAP *in vivo*

To assess the expression pattern of *Sac1 in vivo*, we generated antibodies against two subfragments of the protein. However, these antibodies performed rather poorly, so we generated transgenic flies expressing a functional *Flag-Sac1* construct, which rescued the lethality of *Sac1²¹⁰⁷* mutants and facilitated *Sac1* localization using Flag-specific antibodies. We found that both *Sac1* and DVAP proteins colocalized in larval brains, eye imaginal discs and salivary glands (Supplementary Material, Fig. S9A, C and D). DVAP and *Sac1* closely associated in muscles where they colocalized in a perinuclear region (Supplementary Material, Fig. S9B) that has been previously shown to correspond to the ER/sarcoplasmic reticulum (3).

In yeast and mammalian cells, *Sac1* associated with the ER and the Golgi (35,36). To define the subcellular localization of *Drosophila Sac1*, we cotransfected *Flag-Sac1* and *Myc-DVAP* constructs in COS-7 cells. Staining with antibodies specific for DVAP and Flag revealed a considerable overlap of the two proteins in a reticular pattern that previous studies showed to be the region where DVAP overlapped with ER-specific markers (3). *Sac1* also localized to a paranuclear region corresponding to the Golgi complex. DVAP staining appeared to be excluded from this region, confirming that DVAP was predominantly an ER-associated protein (Supplementary Material, Fig. S9E). Finally, to define the subcellular localization of *Sac1 in vivo*, we targeted expression of *Flag-Sac1* in salivary glands. Consistent with the COS-7 data, *Sac1* partially

colocalized with both the ER marker Boca (37) and the cis-cisternal Golgi marker GM130 (Supplementary Material, Fig. S10). In summary, these data indicate that DVAP and Sac1 colocalize in all the tissues examined. Moreover, Sac1, like its yeast and mammalian homologues, associates with subcellular compartments corresponding to both the Golgi and the ER.

DVAP function is required to maintain normal PtdIns4P levels

In mammals, Sac1 controls PtdIns4P levels in the ER and in the Golgi, and in yeast, it can also modulate PtdIns4P associated with the plasma membrane (PM) (17,38). In yeast, VAP is required for Sac1 activity, and in VAP mutants PtdIns4P levels are increased (39). If such a mechanism were conserved in *Drosophila*, then one would also expect an increase in PtdIns4P levels in *DVAPRNAi^{GD3990}* mutants. We first stained larval salivary glands with a PtdIns4P antibody. In control cells, PtdIns4P was mainly detected at the PM, while under these staining conditions the intracellular pool was barely detectable. In contrast, both *elav;Sac1RNAi* and *elav;DVAPRNAi^{GD3990}* salivary glands exhibited increased PtdIns4P levels, particularly intracellularly (Supplementary Material, Fig. S11A). In control brains and muscles, PtdIns4P levels were basically below our detection limit (Supplementary Material, Fig. S11B and C). However, in *Sac1RNAi* and *DVAPRNAi^{GD3990}* brains, the expression levels of PtdIns4P were dramatically increased (Supplementary Material, Fig. S11B). In *BG57;Sac1RNAi* and *BG57/DVAPRNAi^{GD3990}* muscles, a similar increase in PtdIns4P levels was observed (Supplementary Material, Fig. S11C). These results support a role for DVAP in PtdIns4P metabolism, potentially by controlling Sac1 phosphatase function.

The mutant phenotypes associated with both pre- and postsynaptic expression of *DVAP-P58S* (Supplementary Material, Figs S1, S6 and S7) were highly similar to those of *DVAPRNAi* and *Sac1RNAi* in the same tissues. We should expect then to observe increased PtdIns4P levels in *DVAP-P58S* flies. Indeed, PtdIns4P levels were dramatically elevated in salivary glands, brains and muscles expressing the *DVAP-P58S* transgene (Supplementary Material, Fig. S11A–C). Finally, we showed that in every genotype the increase in PtdIns4P levels was not accompanied by a significant upregulation of PtdIns(4,5)P₂, suggesting that the observed phenotypes are unlikely to be mediated by an upregulation of PtdIns(4,5)P₂ (Supplementary Material, Fig. S12). Hence, these data indicate that DVAP function is required for PtdIns4P metabolism at the NMJ and that transgenic expression of ALS-causing mutations associates with an upregulation of PtdIns4P levels both in neurons and muscles.

Downregulation of *Sac1* in neurons causes dosage-dependent neurodegeneration

Flies expressing *DVAP-P58S* in the adult nervous system fail to eclose, whereas targeted expression of *DVAP-P58S* in the eye induces extensive neurodegeneration, characterized by reduced eye size, with disorganized ommatidia showing missing, irregular or supernumerary bristles (3). As *DVAP-P58S* expression induces an increase in PtdIns4P levels and causes extensive

neurodegeneration, one would expect the same outcome from Sac1 downregulation in neurons.

To test this hypothesis, we downregulated *Sac1* in the nervous system, using the *elav-Gal4* driver (*elav;Sac1RNAi*). Accordingly, *elav;Sac1RNAi* flies failed to eclose in 60% of individuals, whereas survivors exhibited marked neurodegeneration in the eye. The extent of neurodegeneration was, however, different in males and females. Females displayed extensive depigmentation, whereas males had the majority of the eye surface covered by patches of severe necrosis (Fig. 4A). The necrotic patch phenotype was fully penetrant as it was observed in 100% of males; however, differences in the degree and extent of the necrotic regions could be seen. The gender difference was consistent with higher levels of *elav-Gal4* expression in males than in females owing to the X-chromosome dosage compensation effect in males (40). No difference in eye tissue survival between *elav-Gal4* females and males was observed, indicating that the degenerative phenotype was not dependent on differences in gender or expression of *Gal4* alone. Scanning electron micrographs of male eyes showed extensive regions of fused ommatidia and missing or misoriented interommatidial bristles (Fig. 4B). Eye sections showed a severe disruption in retinal organization, with thinning of the retina and loss of retinal neurons (Fig. 4C). This degenerative phenotype correlated with increased levels of PtdIns4P in *elav;Sac1RNAi* eye imaginal discs (data not shown).

In *Sac1* mutant clones, activation of pro-apoptotic caspase 3 is suppressed by simultaneously overexpressing the *Drosophila* Inhibitor of Apoptosis 1 (*DIAP1*) gene (41). Likewise, *DIAP1* overexpression strongly suppressed the reduction in eye size associated with *DVAP-P58S* expression in the eye. This suppression was not due to a dilution of *Gal4*, as coexpression of a *GFP* transgene had no effect (Supplementary Material, Fig. S13). These data indicate that in both cases neurodegeneration was, at least in part, due to death by apoptosis. In conclusion, these data demonstrate that *Sac1* downregulation induces neurodegeneration in a dosage-dependent manner and that a similar phenotype is associated with transgenic expression of *DVAP-P58S* in neurons.

Upregulation in PtdIns4P levels induces *DVAP-P58S*-associated synaptic phenotypes and neurodegeneration

Our data so far indicate that upregulation of PtdIns4P could be a major cause of *DVAP-P58S*-mediated neurodegeneration. If this were true, then one would expect that blocking PtdIns4P production by downregulating either of the two PtdIns-kinases, *PI4KIIIα* and *Four-wheel drive* (*Fwd*), should suppress neurodegeneration. Coexpressing either *FwdRNAi* or *PI4KIIIαRNAi* transgenes in *ey,DVAP-P58S* recombinant flies markedly attenuated the neurodegenerative phenotype. Specifically, the structural phenotypes and ~50% size reduction in *ey,DVAP-P58S* eyes were significantly suppressed in both *ey,DVAP-P58S/PI4KIIIαRNAi* and *ey,DVAP-P58S;FwdRNAi* flies (Fig. 5). This suppression was not due to a dilution of *Gal4*, as coexpression of a *GFP* transgene had no effect (Supplementary Material, Fig. S13).




Figure 4. Downregulation of *Sac1* in the eye induces neurodegeneration in a dosage-dependent manner. (A) Stereo microscope images of control (*elav-Gal4/+*), *elav;Sac1RNAi* male and *elav;Sac1RNAi* female adult eyes. (B) Scanning electron micrographs of control and *elav;Sac1RNAi* transgenic eyes of adult males. Although the adult *Drosophila* eye is composed of an ordered array of ommatidia with interspersed, regularly oriented bristles, transgenic eyes exhibit extensive regions of fused ommatidia (black arrow), with missing (black arrow) and misoriented bristles (white arrow). (C) Frontal sections of control and *elav;Sac1RNAi* transgenic eyes of adult males. The arrowhead points to tissue degeneration. Bar = 10 μ m in (B) and 50 μ m in (A) and (C).

To directly confirm the role of PtdIns4P in *DVAP-P58S*-induced neurodegeneration, we assessed PtdIns4P levels in eye imaginal discs of *ey,DVAP-P58S*; *ey,DVAP-P58S/PI4KIII α RNAi* and *ey,DVAP-P58S;FwdRNAi*. A marked increase in PtdIns4P levels was observed in *ey,DVAP-P58S* eye imaginal discs, whereas PtdIns4P levels were reduced and similar to wild-type in *ey,DVAP-P58S/PI4KIII α RNAi* and *ey,DVAP-P58S;FwdRNAi* animals (Fig. 6A, B, D and E). The decrease in the PtdIns4P levels was not a consequence of diluting the *Gal4*, as coexpression of a *GFP* transgene with *DVAP-P58S* had no effect (Fig. 6C).

Synaptic phenotypes associated with the expression of *DVAP-P58S* in the motor system could also be due to an upregulation of PtdIns4P and therefore knocking down either *Fwd* or *PI4KIII α* kinase should suppress *DVAP-P58S*-mediated phenotypes. In both cases, the motor neuron-specific driver *OK6-Gal4* was used. We found that the NMJ phenotypes of *OK6;DVAP-P58S* were significantly rescued by coexpressing the *FwdRNAi* transgene (Fig. 7). A similar effect was observed when *PI4KIII α RNAi* was expressed in motor neurons together with *DVAP-P58S* (data not shown). In addition, the effect of coexpressing *FwdRNAi* and *DVAP-P58S* transgenes in muscles (*BG57/DVAP-P58S;FwdRNAi*) was assessed. Interestingly, we found that *BG57/DVAP-P58S;FwdRNAi* NMJs did not resemble wild-type but rather NMJs expressing *BG57;FwdRNAi* alone. Specifically, NMJs exhibited an abnormal structure and were composed mainly of a few fused

boutons lacking their characteristic smooth and round shape. These boutons appeared deformed, with elongated and misshapen profiles (Supplementary Material, Fig. S14A–C). This phenotypic similarity suggests that *FwdRNAi* expression in *BG57/DVAP-P58S* postsynaptic terminals decreased PtdIns4P below wild-type levels. An analogous effect was observed when *PI4KIII α RNAi* transgene was expressed in *BG57/DVAP-P58S* muscles (data not shown). Interestingly, we found that presynaptic and postsynaptic coexpression of *FwdRNAi* transgene in *DVAPRNAi^{GD3990}* NMJs had a similar effect, further supporting the importance of PtdIns4P levels in *DVAP*-mediated function (Supplementary Material, Figs S15 and S14D, respectively). In conclusion, these data provide strong evidence for a direct role of PtdIns4P upregulation in *DVAP-P58S*-mediated neurodegeneration and synaptic phenotypes.

Sac1 is sequestered in DVAP-P58S-induced aggregates

Our biochemical data and the analysis of mutant phenotypes indicate that ALS8 is due to *DVAP* loss-of-function, with *Sac1* being downregulated and PtdIns4P levels subsequently increasing. However, our biochemical analysis also showed that both ALS8 mutations retain their ability to bind *Sac1*. How then is *Sac1* function impaired in *DVAP-P58S* mutants? To address this question, we coexpressed a *Flag-Sac1* transgene in *ey-Gal4,DVAP-P58S* recombinant flies and stained eye imaginal discs with antibodies specific for Flag and DVAP. We have previously shown that *DVAP-P58S*-mediated aggregates contain wild-type and mutant DVAP proteins that are both immunoreactive to DVAP-specific antibodies (3). We observed that, in larval eye imaginal discs, *Sac1* was sequestered in the *DVAP-P58S*-mediated inclusions and was depleted from its normal localization (Fig. 8A). Similarly, in *elav;DVAP-P58S;Flag-Sac1* larval brains, *Sac1* appeared to be recruited into *DVAP-P58S*-mediated aggregates (Fig. 8B). This was in contrast to the diffuse and granular pattern of *Sac1* staining observed in controls (Supplementary Material, Fig. S9A and C). In both instances, the association of *Flag-Sac1* with the aggregates was specific since a coexpressed GFP was not recruited into the aggregates (data not shown). In conclusion, our data indicate that the *DVAP-Sac1* interaction regulates PtdIns4P levels and support a model whereby sequestering *Sac1* and DVAP into pathogenic aggregates compromises the function of both proteins, leading to an increase in PtdIns4P levels.

DISCUSSION

Here we identified *Sac1* as a DVAP-binding protein and uncovered a hitherto unknown function of *Sac1* in postembryonic synaptic maturation and neurodegeneration. Presynaptic reduction of either DVAP or *Sac1* levels induces structural changes, disruption of the synaptic MT cytoskeleton and accumulation of clusters of proteins and vesicles along the axons. In addition, muscle downregulation of either *Sac1* or DVAP leads to a strikingly aberrant synaptic morphology and abnormal localization and distribution of several postsynaptic markers, including adducin and β -spectrin. We also report




Figure 5. *DVAP-P58S*-mediated neurodegeneration is rescued by downregulating either *PI4KIIIα* or *Fwd* PI4-kinases. (A) Stereo microscope images, (B) frontal sections and (C) scanning electron micrographs of adult fly eyes of the following genotypes: controls (*ey-Gal4/+*), *ey,DVAP-P58S*, *ey,DVAP-P58S/PI4KIIIαRNAi* and *ey,DVAP-P58S;FwdRNAi*. Whereas control eyes are composed of ommatidia and regularly spaced mechanosensory bristles (C), *ey,DVAP-P58S* eyes are smaller (A) with missing (arrowhead in C), supernumerary (black arrow in C) bristles and occasionally fused ommatidia. In (B), white arrow points to tissue degeneration. The *ey,DVAP-P58S*-mediated neurodegeneration is rescued by downregulating either *PI4KIIIα* or *Fwd*. (D) Quantification of the eye surface area of every genotype. The reduced eye size of *ey,DVAP-P58S* flies is significantly suppressed by coexpressing either *PI4KIIIα* (*ey,DVAP-P58S/PI4KIIIαRNAi*) or *FwdRNAi* (*ey,DVAP-P58S;FwdRNAi*). Bar = 50 μm in (A) and (B) and 10 μm in (C). Error bars denote SEM. *n* = 25 eyes per genotype. ****P* < 0.001.

that depletion of DVAP as well as *Sac1* expression induces an increase in PtdIns4P levels.

We go on to show that *Sac1* downregulation in the adult nervous system causes early death and neurodegeneration in a dosage-dependent manner, a phenotype similar to that of *DVAP-P58S* transgenic expression. Our analysis indicates that the *DVAP-P58S* allele has a dominant negative effect, as its transgenic expression leads to an upregulation of PtdIns4P and its mutant phenotypes are similar to those associated with either *DVAP* or *Sac1* loss-of-function. In agreement with the hypothesis that neurodegeneration in the

DVAP-P58S context is due to a loss-of-function of both *DVAP* and *Sac1*, we report that both wild-type DVAP and *Sac1* are depleted from their normal localization and are sequestered into DVAP-P58S-mediated aggregates.

Altogether, these data are consistent with a model in which *DVAP* is required for *Sac1* activity and for the regulation of intracellular PtdIns4P levels. Loss-of-function of *DVAP* and *Sac1* by a *DVAP-P58S*-mediated dominant-negative mechanism induces cell degeneration by an upregulation of PtdIns4P, which is also responsible for the observed disruption of fundamental biological processes at the NMJs (Fig. 8C).

We and others have previously shown that transgenic expression of DVAP proteins carrying the equivalent ALS8 mutations in *Drosophila* mimic the human disease (3,6,9). Notably, expression of hVAPB in flies rescues the lethality and the phenotypes associated with DVAP mutants, indicating an evolutionarily conserved function for VAP proteins (6).

Collectively, these data indicate that DVAP-mediated molecular pathways are likely to be important for our understanding of the disease pathogenesis in humans.

DVAP and *Sac1* interact to control PtdIns4P levels

There is evidence supporting that DVAP functions to maintain normal cellular levels of PtdIns4P by interacting with *Sac1*. First, *Sac1* and DVAP bind to each other and colocalize in many different tissues. It has been reported that phosphoinositol transfer proteins/phosphoinositide-binding proteins associate directly with phosphatases and kinases to control their activities (39,42,43). Specifically, VAP has been shown to bind PtdIns4P *in vitro* (44) and to be required for *Sac1* activity in yeast (39). Second, PtdIns4P levels are upregulated in *DVAPRNAi* mutants, suggesting that *DVAP* function is required for normal PtdIns4P levels. Similarly, in yeast, inactivation of *Scs2/Scs22* VAP genes induces an increase in the levels of PtdIns4P (39,45). Third, the phenotypic similarity associated with either *DVAP* or *Sac1* loss-of-function mutations supports the idea that the pool of PtdIns4P that is upregulated in *DVAP* mutants is the same as the one dephosphorylated by *Sac1*.

Previous studies attributed a prominent functional role to the N-terminal MSP domain of DVAP. The MSP domain is cleaved and secreted and binds to the extracellular domain of Ephrin receptors (7). Secreted MSP also binds to Robo and Lar-like receptors to control mitochondria morphology, localization and function in muscles (8). We identified a new DVAP-binding activity that is MSP-independent and involves a C-terminal fragment encompassing the TM domain. Interestingly, a new hVAPB mutation replacing valine at position 234 with an isoleucine in the conserved TM domain of hVAPB has been shown to cause ALS8 in humans (46). These data may provide direct evidence of a role of hVAPB-*Sac1* interaction in the disease pathogenesis in humans.

Dynamic localization of *Sac1* and ER/PM contact sites

In yeast and mammalian cells, *Sac1* is an integral membrane protein localized to the ER and the Golgi (17,36,47). Here we report a similar localization for the *Drosophila* homologue of *Sac1*. In yeast and mammalian cells, *Sac1* localization




Figure 6. Suppression of *DVAP-P58S*-mediated neurodegeneration by *FwdRNAi* and *PI4KIIIαRNAi* correlates with a decrease in PtdIns4P levels. (A–E) Representative confocal images of eye imaginal discs stained with an antibody specific to PtdIns4P phosphoinositides from *ey-Gal4/+* control larvae in (A), *ey,DVAP-P58S* larvae in (B), *ey,DVAP-P58S/GFP* larvae in (C), *ey,DVAP-P58S/PI4KIIIαRNAi* larvae in (D) and *ey,DVAP-P58S;FwdRNAi* larvae in (E). The control levels of PtdIns4P are barely detectable in our experimental conditions, but there is a massive upregulation of PtdIns4P levels in *ey,DVAP-P58S* eye imaginal discs. A decrease in PtdIns4P levels is observed when either the *PI4KIIIα* or *Fwd* kinases are downregulated in eye imaginal discs expressing *DVAP-P58S*, whereas coexpression of a *GFP* transgene has no effect. Bar = 50 μm.

appears to be very dynamic, as this protein shuttles between ER and Golgi upon nutrient conditions. Specifically, glucose starvation in yeast or growth factor deprivation in mammalian cells causes relocalization of Sac1 from the ER to the Golgi complex, where it reduces PtdIns4P levels and slows protein trafficking (38). The ER–Golgi shuttling ability of Sac1 is reversed when nutrients or growth factors are added back to the growth medium (38). The growth factor-induced translocation of Sac1 from the Golgi to the ER requires p38 MAPK (mitogen-activated protein kinase) activity (48). These data suggest that Sac1 trafficking may be regulated by stressors that activate p38 MAPK. Some of these stressors such as oxidative damage and ER stress are triggers of neurodegeneration (49). This raises the intriguing possibility that a p38 MAPK-activated mechanism of PtdIns4P spatial regulation may be implicated in neurodegenerative processes.

A paper published after our paper was submitted revealed that Scs2/Scs22 VAP proteins in yeast play a pivotal role in tethering the ER to the PM to form ER/PM contact sites (45). Recent studies have highlighted the role of membrane junctions between organelles as important sites for lipid metabolism and intracellular signalling controlled by PtdIns4P (50). Depletion of Scs2/Scs22 VAP proteins located to the ER/PM contact sites leads to a retraction of the ER into internal structures, elevated levels of PtdIns4Ps at the PM and induction of the UPR (45). At the ER/PM contact sites, Sac1 dephosphorylates PtdIns4P on the PM in trans from the ER (39). This reaction requires the Scs2/Scs22p VAP proteins and the oxysterol-binding homology proteins that act as PtdIns4P sensors and activates Sac1 phosphatase activity

(39). ER/PM junctions have been described in many organisms and cell types, including neurons and *Drosophila* photoreceptors (51,52). In addition, VAP proteins have been implicated in ER–Golgi, ER–endosomes and ER–mitochondria contacts in mammalian cells, suggesting that they may function as a tether for several organelle/membrane contact sites (53–55).

In conclusion, emerging evidence suggests that VAP proteins may be a crucial component of a hub controlling PtdIns4P metabolism in yeast and possibly, in higher eukaryotes as well.

The role of PtdIns4P in synaptic physiology and neurodegeneration

The ability of either *PI4KIIIα* or *Fwd* to suppress the synaptic and neurodegenerative phenotypes associated with transgenic expression of *DVAP-P58S* is somewhat surprising, as their yeast homologues (*Stt4* and *Pik1*, respectively) are supposed to play non-redundant functions and to control spatially separate pools of PtdIns4P. This is based on previously published data showing that, in yeast, *Stt4* and *Pik1* are both essential for cell viability but control different cellular processes (56–58). *Pik1* is essential for anterograde vesicular trafficking (59), whereas *Stt4* plays a role in actin cytoskeleton organization and protein kinase C signalling (57). Both *Pik1* and *Stt4* play distinct roles in regulating MAPK signalling (60,61). Localization studies further suggest that *Pik1p* is primarily present in the nucleus and in the Golgi, whereas *Stt4p* is mainly cytoplasmic and is recruited to the PM for localized synthesis of PtdIns4P (56,57,59).




Figure 7. Downregulation of *Fwd* PI4-kinase in neurons rescues the *DVAP-P58S* presynaptic phenotypes. (A–C) Representative confocal images of NMJs stained for HRP and Futsch in *OK6-Gal4/+* control (A), in *OK6/DVAP-P58S* larvae (B) and in *OK6/DVAP-P58S;FwdRNAi* larvae (C). (D–F) Representative confocal images of nerves stained for HRP and Brp antibodies in *OK6-Gal4/+* control (D), in *OK6/DVAP-P58S* larvae (E) and in *OK6/DVAP-P58S;FwdRNAi* larvae (F). (G) Quantification of bouton size at muscle 12 (type I and type III boutons) of segment A3 in *OK6-Gal4/+* control, *OK6/DVAP-P58S* and *OK6/DVAP-P58S;FwdRNAi* NMJs ($n = 205, 149, 286$, respectively). (H) Quantification of total number of boutons on muscle 12 and 13 of segment A3 in *OK6-Gal4/+* controls ($287.4 \pm 3.2, n = 10$), *OK6/DVAP-P58S* ($160.9 \pm 1.4, n = 10$) and *OK6/DVAP-P58S;FwdRNAi* ($265 \pm 3, n = 10$) NMJs. The decrease in number of boutons and the increase in their size in *OK6/DVAP-P58S* are significantly rescued by downregulating *Fwd* ($P < 0.0001$ in every case). Presynaptic downregulation of *Fwd* kinase rescues the morphological, the MT and the axonal transport phenotypes associated with both *DVAP-P58S* presynaptic downregulation. Bar = 10 μm. Error bars denote SEM. *** $P < 0.0001$.

However, at present, the precise degree to which Stt4 and Pik1 functions have been conserved and apportioned among their homologues in flies remains unclear.

In *Drosophila*, the *Stt4* homologue *PI4KIIIα* is required for oocyte polarization and its intracellular localization has not been determined (62). On the other hand, previous studies revealed that the fly *Pik1* homologue *Fwd* is required for male germ-line cytokinesis (63). In spermatocytes, *Fwd* localizes to the Golgi and it is required for the accumulation of PtdIns4P on this organelle, implying that its function in providing PtdIns4P in the Golgi is evolutionarily conserved with yeast (64). However, whereas *Pik1* is required for cell viability, *Fwd* appears to be dispensable for normal development, suggesting that it is redundant with similar genes in carrying out its function (56,64–66).

Another way to explain the rescue data would be to admit that upregulation of PtdIns(4,5)P₂ and not PtdIns4P is responsible for *DVAP-P58S* mutant phenotypes.

PtdIns4P formed by the PM-associated STT4 can function as a substrate of PI4P 5-kinase to generate PtdIns(4,5)P₂ at the cell cortex (15). It is also possible that PtdIns4P that is phosphorylated by plasmalemmal PI4P 5-kinase originates from intracellular sources. In the Golgi, PtdIns4P levels play a central role in the formation of vesicles delivered from the trans-Golgi network to the PM and their lipid cargo could be the substrate for the plasmalemmal PtdIns(4,5)P₂ synthesis (67). As PtdIns4P in the Golgi is mainly produced by Pik1 it is therefore possible that PtdIns(4,5)P₂ associated with the PM and its effector proteins are downstream of both Stt4 and Pik1. Moreover, upregulation of PtdIns(4,5)P₂ would explain the MT phenotypes, the mislocalization of post-synaptic markers and the axonal transport defects. Indeed, PtdIns(4,5)P₂-enriched microdomains in the PM have been shown to participate in the regulation of MT plus-end capture and stabilization during polarized motility (68). In *Caenorhabditis elegans*, the microtubular motor UNC-4




Figure 8. Sac1 is sequestered into DVAP-P58S-mediated aggregates. (A) Eye imaginal discs and (B) brains stained for both DVAP and Flag in *ey,DVAP-P58S/Flag-Sac1* and *elav,DVAP-P58S/Flag-Sac1* larvae. Bar = 10 μ m. (C) Graphical summary of the data. The left panel shows a chemical equilibrium between two reactions: one in which Sac1 interacts with DVAP to catalyse the conversion of PtdIns4P into PtdIns and another in which PI4K converts PtdIns into PtdIns4P. The right panel shows that depleting DVAP (i) or Sac1 (ii) or the aggregation of Sac1 and DVAP into DVAP-P58S-induced aggregates (iii) inhibits Sac1-mediated reaction leading to an increase in PtdIns4P levels.

gene was shown to be anchored to synaptic vesicles, using a pleckstrin homology domain, thus implicating PtdIns(4,5) P_2 in MT-based intracellular motility (69). Finally, spectrin proteins and adducin require PtdIns(4,5) P_2 for their correct localization to the cell cortex (29,31).

However, if this were true, we should observe an increase in PtdIns(4,5) P_2 levels wherever we observe an upregulation of PtdIns4P. By using an antibody specific for PtdIns(4,5) P_2 , we quantified PtdIns(4,5) P_2 levels in tissues in which either *Sac1* or *DVAP* were downregulated as well as in tissues expressing the *DVAP-P58S* transgene. Surprisingly, PtdIns(4,5) P_2 levels were not affected by the dramatic upregulation of PtdIns4P in any of the genotypes described earlier. Consistent with these data, it was previously reported that, in *Drosophila* eye imaginal discs, depletion of *Sac1* exhibits a dramatic increase in PtdIns4P levels, whereas PtdIns(4,5) P_2 and PtdIns3P levels remain similar to wild-type (41). In addition, a paper published after our paper was submitted and another paper published a few months earlier showed that loss of PM PtdIns4P by downregulation of *PI4KIII α* was not matched by a decrease in PtdIns(4,5) P_2 levels (70,71). They showed that the major function of PtdIns4P is not to generate the pool of PtdIns(4,5) P_2 on the PM but rather to contribute to the generation of a polyanionic lipid environment in the inner leaflet of the PM. PtdIns4P would then function in recruiting soluble proteins to the PM by electrostatic interaction with their polycationic surface. They also show that

PtdIns4P contributes to processes such as modulation of ion channel activity that have been traditionally associated with changes in PtdIns(4,5) P_2 (71). Finally, upregulation of PtdIns(4,5) P_2 by inactivation of the *Drosophila* PI(4,5) P_2 5-phosphatase synaptojanin leads to a distinct endocytotic phenotype due to defects in synaptic vesicle recycling. In synaptojanin mutants, synaptic vesicles are severely depleted and those remaining are clearly clathrin-coated. Intracellular recordings revealed enhanced synaptic depression during prolonged high-frequency stimulation (72). Ultrastructural and electrophysiological analysis of *DVAP* mutants do not exhibit a synaptojanin-like phenotype (6,9 and G. Pennetta, unpublished data), indicating that upregulation of PtdIns(4,5) P_2 does not mimic the phenotype associated with increased levels of PtdIns4P.

Taken together, these considerations suggest that increased levels of PtdIns4P could be the main factor determining the observed synaptic and neurodegenerative phenotypes. Further studies using fluorescent phosphoinositide probes and genetic analyses will be needed to fully clarify the contribution of PtdIns4P versus PtdIns(4,5) P_2 pools to NMJ physiology and neurodegeneration.

The role of DVAP–Sac1 interaction in lipid transport

Emerging evidence indicates that VAP and Sac1 may also play an important and specific role in membrane homeostasis (73).

Biogenesis of sphingolipids, sterols and phosphoinositides that together determine the structural and functional properties of cell membranes must be closely coordinated. VAP interacts with both oxysterol-binding protein (OSBP) and ceramide transfer protein (CERT), recruiting them to contact sites between the ER and the Golgi complex (74). CERT has a FFAT (diphenylalanine in an acidic tract) motif that mediates its binding to ER-localized VAP and a PH domain that recognizes the PtdIns4P-enriched Golgi membrane. It has been proposed that CERT, because of its dual-binding ability, shuttles ceramide from the ER to the Golgi, where it is converted into sphingomyelin (75). Sphingomyelin continues to move through the secretory pathway to the PM, where it is most abundant. OSBP has an analogous function to CERT but instead mediates inter-membrane sterol transfer. This functional similarity is also reflected in OSBP's domain architecture: like CERT, it contains a PtdIns4P-binding PH domain and a VAP-binding FFAT motif (76). Ridgway and Perry (74) showed that sterols regulate sphingolipid metabolism by inducing a significant increase in SM synthesis that is dependent on OSBP, CERT and their shared binding partner VAP. The precise mechanism is not yet known but OSBP appears to activate CERT by promoting its recruitment to membranes and its binding to VAP. It is likely that disruption of the VAP–Sac1 interaction may have profound effects on the lipid composition of the PM, affecting its curvature and thickness and by consequence, vesicle budding and membrane remodelling (77). Interestingly, synaptic growth requires membrane remodelling and, at the *Drosophila* NMJs, occurs mainly by the budding of new boutons from pre-existing ones (78).

Putative roles of PtdIns4P in neurodegeneration

VAPB is involved in the IRE1/XBP1 signalling pathway of the UPR, an ER reaction inhibiting the accumulation of unfolded/misfolded proteins. In the disease-context, the hVAPB-P56S protein recruits its wild-type counterpart into the aggregates and it attenuates its ability to induce the UPR (10). This together with the observation that, in yeast, depletion of VAP proteins from the ER/PM contact sites induces a constitutive activation of the UPR suggests that motor neurons in ALS8 could be particularly vulnerable to cell death-induced ER stress. In addition, VAP proteins have been shown to be involved in lipid transfer and metabolism and accumulation of lipids and intermediates of lipid biosynthetic pathways are potent inducers of apoptosis (79). Finally, recent studies in yeast have shown that defects in the PtdIns4K Pik1 activity lead to a blockage of autophagy, a process controlling the degradation of long-lived proteins, damaged organelles and bulk cytoplasm in response to various types of stress (80).

Many questions remain to be explored concerning the precise molecular mechanism underlying neurodegeneration in ALS. However, over the last few years, an increasing number of experimental models have been generated and they represent an excellent tool for identifying molecular pathways in ALS and for evaluating their contribution to the disease pathogenesis.

MATERIALS AND METHODS

Drosophila stocks

Flies were raised on standard cornmeal food at 25°C. The following strains were used: *elav-Gal4*, *ey-Gal4*, *OK6-Gal4*, *BG57-Gal4* and *UAS-DIAP1* and the *DVAPRNAi^{JF02621}* (Bloomington *Drosophila* Stock Center) and *Sac1²¹⁰⁷* (19). *Sac1RNAi*, *PI4KIIIαRNAi*, *DVAPRNAi^{GD3990}* and *FwdRNAi* stocks were obtained from the VDRC. For the *DVAPRNAi^{JF02621}* line, the P{TRiP.JF02621} construct was used and the target sequence is in the 3' UTR of the cDNA, whereas the P{GD3990} construct used for the *DVAPRNAiGD³⁹⁹⁰* line has a target sequence located within the ORF of the DVAP cDNA (<http://flybase.org>).

Immunohistochemistry

NMJs from wandering third-instar larvae were dissected in cold PBS before fixation and staining as previously described (5). The PtdIns4P staining and PtdIns(4,5)P₂ staining were performed as previously reported (41) with tissue-specific modifications. For PtdIns4P and PtdIns(4,5)P₂ staining, tissues were fixed with 4% paraformaldehyde in PBS for 30 min, then washed in PBS and quenched with 50 mM NH₄Cl in PBS for 10 min, before washing. Salivary glands were permeabilized in TBS + 0.5% saponin (Sigma) for 1 h at room temperature before blocking overnight in TBS with 0.3% saponin and 10% NGS at 4°C. Primary antibodies were used at 1:100 in permeabilization buffer containing 5% NGS for 2 h at room temperature. Primary and secondary antibody washes were carried out in TBS containing 0.3% saponin and 1% NGS. Eye imaginal discs were processed similarly with a 3 h permeabilization and 4 h primary antibody incubation time. Larval brains and NMJs were processed similarly except that the permeabilization and the incubation with the primary antibody were performed overnight at 4°C.

Mouse monoclonal antibodies for Futsch, Adducin, dCSP, Brp and DLG were all used at a concentration of 1:50. Other antibodies were used at the following concentrations: anti-β-spectrin at 1:500, rabbit anti-DLG at 1:8000, anti-Boca at 1:1000, anti-DVAP at 1:1000, anti-GM130 (Abcam) at 1:100, anti-Flag (Sigma) at 1:100 and anti-PtdIns4P (Echelon) at 1:100. Goat anti-HRP (1:200), rabbit anti-HRP (1:500) and all secondary antibodies (1:500) were purchased from Jackson ImmunoResearch. Samples were mounted on microscope slides using Vectashield mounting medium (Vector Laboratories).

Eye histology and scanning electron microscopy

Frontal sections and scanning electron microscopy of adult fly eyes were processed as previously described (3).

Molecular biology

To generate the N-terminal Flag-tagged Sac1 (*Flag-Sac1*) construct, the full-length *Sac1* cDNA was amplified from clone GH08349 with PCR primers containing *Bam*HI and *Sal*I sites and cloned in-frame into the *pCMV-Tag2b* vector (Clontech). The *Flag-Sac1* fragment was then cloned into the *pUAST* vector using *Not*I and *Kpn*I sites. For

co-immunoprecipitation experiments, the *Myc-Sac1* construct was generated by PCR amplification of the full-length *Sac1* cDNA, using primers containing *SalI* and *KpnI*. The resulting fragment was cloned in-frame into *pCMV-Myc* vector (Clontech). The Flag-tagged DVAP (*Flag-DVAP*) construct was generated by amplifying the full-length *DVAP* cDNA with PCR primers containing *EcoRI* and *SalI* sites and by cloning the resulting DNA fragment in-frame into the *pCMV-Tag2b* vector. The *DVAP-P58S* construct was cloned into the *pCMV-Tag2b* vector, using the same strategy as for the cloning of *DVAP* cDNA in the same vector. For immunocytochemistry, a *Myc-DVAP* construct was generated by PCR amplification of the full-length *DVAP* cDNA, using *EcoRI* and *NotI* primers and cloned in-frame into *pCMV-Myc* vector (Clontech). For the same experiment, the *Flag-Sac1* fragment was cloned into the *pCMV-Tag2b* vector as described earlier. For the semiquantitative PCR amplification, total RNA was purified from 20 dissected brains of the relevant genotypes and collected in TRIzol reagent (Sigma). cDNAs were produced using oligo-dT primers and following the manufacturer's instructions (SuperScript III First Strand Kit, Invitrogen). Amplification of Rp49 cDNA was made using the following primers: Rp49-L: CCGACCACGTTAC AAGAACTCTC; Rp49-R: CGCTTCAAGGGACAGTATCT GA. For the amplification of *Sac1* cDNA, the following primers were used: *Sac1*-L: TGCTGGGAACCATTCACCTA and *Sac1*-R: TGGCACTGACAGCG ATCATT. In both cases, PCR conditions were in the linear part of amplification. At least three different samples for each genotype were analysed. PCR products were visualized with ethidium bromide on a gel. For the *Sac1Δ* construct, the deletion of the RTNCIDCLDRTN catalytic motif was introduced into *Sac1* cDNA (GH08349 clone) by site-directed mutagenesis using QuikChange IIXL Site-Directed Mutagenesis Kit (Agilent Technologies) and following the manufacturer's instructions. The *Sac1*cDNA carrying the RTNCIDCLDRTN motif deletion was isolated by PCR amplification and cloned into pUAST vector, using *BamHI*–*KpnI* linkers. Basic molecular biology techniques were performed following standard protocols.

Co-immunoprecipitation and immunocytochemistry

Cells were cultured in DMEM medium containing 10% FBS until 80% confluent and transfected with the relevant plasmids, using FuGENE Transfection Reagent (Roche) according to the manufacturer's instructions. Protein lysates for co-immunoprecipitation were prepared as previously described in Kawano *et al.* (81), with minor modifications. The protein complexes were immunoprecipitated using anti-Myc beads from Pierce Profound c-Myc Tag IP/Co-IP Application Set (Thermo Scientific). Inputs, precipitated protein complexes and supernatants were analysed by SDS–PAGE and western blots. Detection of Flag-DVAP proteins by western blot was performed by using a guinea pig anti-DVAP antibody at a concentration of 1:40 000 and a secondary HRP-conjugated anti-guinea pig antibody at 1: 60 000. Myc-Sac1 proteins were detected by western blot using a rabbit anti-Myc (Sigma) antibody at a concentration of 1:10 000 and an anti-rabbit HRP-conjugated secondary antibody at 1:30 000. For

immunocytochemistry, cells were plated on BioCoat™ poly-L-lysine glass coverslips (BD Biosciences) and transfected as described earlier. Confluent cells were fixed in 4% paraformaldehyde for 20 min, blocked in PBS-T containing 10% NGS and incubated overnight with both rabbit anti-Myc (Sigma, 1:200) and mouse anti-Flag (Sigma, 1:200) antibodies. Fluorescent secondary antibodies were used at 1:500. Preparations were mounted in Vectashield medium.

Genetics and transgenics

Lethal transgenic insertions were maintained over GFP-containing balancers to select the relevant genotypes for larval phenotypic analysis. Transgenic lines were generated using standard protocols. To characterize the mutant phenotypes, Gal4 drivers were crossed with the transgenic lines. Embryos were collected for 20–24 h and then transferred to a water-bath at 30°C to maximize the expression of the transgene. The *ey-Gal4* driver was recombined with *DVAP-P58S* on the same chromosome, following standard procedures.

Yeast two-hybrid assay

Binary interactions between DVAP and *Sac1* were performed using the MATCHMAKER 3 GAL4 Yeast Two Hybrid System (Clontech). The full-length cDNA for *DVAP* was cloned in-frame into the *pGADT7* vector, using PCR primers containing *EcoRI* and *BamHI* sites. Full-length cDNA for *Sac1* was cloned in-frame into the *pGBKT7* vector, using PCR primers containing *NdeI* and *BamHI* sites. All other fragments were cloned in-frame by PCR, using primers containing *NdeI* and *BamHI* sites. DVAP constructs lacking the CC and TMs were generated by using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) and following the manual's instructions. Protein interactions were analysed in media lacking histidine, adenine, leucine and tryptophan (–HALT medium) following transformation in AH109 yeast strain with the relevant plasmids.

Statistical analysis

Statistical analysis was performed and graphs were generated using GraphPad 5.0. The D'Agostino and Pearson omnibus test was applied to check for normality in the distributions of samples. For experiments with more than two samples which all passed the normality test, a one-way ANOVA test was applied to the samples. Tukey's multiple comparison test was then used as a post hoc-test when a significant difference was found in the ANOVA test. For experiments with more than two samples where at least one did not pass the normality test, statistical analysis was performed using the Kruskal–Wallis test and the Dunn's multiple comparison test as a *post-test*. For experiments with only two samples and where at least one of the two did not pass the normality test, statistical significance was evaluated using the Mann–Whitney *U*-test. Finally, for experiments with only two samples that both passed the normality test, a two-tailed unpaired Student's *t*-test was applied.

Imaging analysis and quantification

For imaging and quantification, NMJs, brains, eye imaginal discs and salivary glands from wandering third instar larvae were dissected and immunostained with the appropriate antibodies. Preparations were imaged on a Zeiss Axiovert LSM510 confocal microscope. The same confocal gain settings were applied to controls and samples. For all the images, the gain was chosen at the maximum gain that did not saturate the signal for each sample. Images were processed with the LSM software and Adobe Photoshop. Quantification of bouton number was performed by counting the total number of boutons on muscle 12 and 13 of the segment A3. The size of boutons was analysed by measuring the surface area of type I and type III boutons on muscle 12 of segment A3 and represented as ratio between the number of boutons with a given range of sizes and the total number of boutons (relative frequency). For the quantification of the axonal transport phenotype and PtdIns(4,5)P₂ levels, a complete Z-stack was acquired and rendered as a maximum projection. Common appropriate intensity thresholds were selected to properly identify specific signals and ignore background intensities in the ImageJ package. The average number of detectable Brp puncta was quantified in 100 µm lengths of segmental nerves by using ImageJ. For the PtdIns(4,5)P₂ levels, detectable puncta in 10⁴ µm² surface areas were quantified. Semi-quantitative analysis of the colocalization was performed and Pearson's overlap coefficient was obtained with the JACoP plugin for ImageJ (82). Characterization of phenotypes in which *elav-Gal4* was used as a driver was performed between gender-matched animals. However, besides the case of the *Sac1* neurodegenerative phenotype, no major differences in phenotypes were observed between males and females in any other context in which *elav-Gal4* was used as a driver.

SUPPLEMENTARY MATERIAL

Supplementary Material is available at *HMG* online.

ACKNOWLEDGEMENTS

We are particularly grateful to Dr Trudy Gillespie for assistance with confocal imaging and to Steven Mitchell for help with scanning electron microscopy analysis. We thank Drs Maria Antonietta De Matteis, Jan Pielage, Richard Ribchester and James Withers for insightful discussions. We are grateful to Luigi Zechini for his technical assistance in the last part of this project. We also thank Dr Jan Pielage, Dr Joaquim Culi and the Developmental Studies Hybridoma Bank for antibodies, the Bloomington *Drosophila* Stock Center and the Vienna *Drosophila* RNAi Center for fly stocks.

Conflict of Interest statement. None declared.

FUNDING

This work was supported by the Wellcome Trust (<http://www.wellcome.ac.uk>) (Pennetta8920), the Motor Neurone Disease Association (MNDA, <http://www.mndassociation.org.uk>) (Pennetta6231) and the Scottish Motor Neurone Disease Association

(SMNDA; <http://www.mndscotland.org.uk>) (Pennetta R4107). Funding to pay the Open Access publication charges for this article was provided by the Wellcome Trust.

REFERENCES

1. Pasinelli, P. and Brown, R.H. (2006) Molecular biology of amyotrophic lateral sclerosis: insights from genetics. *Nat. Rev. Neurosci.*, **7**, 710–723.
2. Nishimura, A.L., Mitne-Neto, M., Silva, H.C.A., Richieri-Costa, A., Middleton, S., Cascio, D., Kok, F., Oliveira, J.R.M., Gillingwater, T., Webb, J. *et al.* (2004) A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. *Am. J. Hum. Genet.*, **75**, 822–831.
3. Chen, H.-J., Anagnostou, G., Chai, A., Withers, J., Morris, A., Adhikaree, J., Pennetta, G. and De Bellerche, J.S. (2010) Characterization of the properties of a novel mutation in VAPB in familial amyotrophic lateral sclerosis. *J. Biol. Chem.*, **285**, 40266–40281.
4. Lev, S., Ben Halevy, D., Peretti, D. and Dahan, N. (2008) The VAP protein family: from cellular functions to motor neuron disease. *Trends Cell Biol.*, **18**, 282–290.
5. Pennetta, G., Hiesinger, P.R., Fabian-Fine, R., Meinertzhagen, I.A. and Bellen, H.J. (2002) *Drosophila* VAP-33A directs bouton formation at neuromuscular junctions in a dosage-dependent manner. *Neuron*, **35**, 291–306.
6. Chai, A., Withers, J., Koh, Y.H., Parry, K., Bao, H., Zhang, B., Budnik, V. and Pennetta, G. (2008) hVAPB, the causative gene of a heterogeneous group of motor neuron diseases in humans, is functionally interchangeable with its *Drosophila* homologue DVAP-33A at the neuromuscular junction. *Hum. Mol. Genet.*, **17**, 266–280.
7. Tsuda, H., Han, S.M., Yang, Y., Tong, C., Lin, Y.Q., Mohan, K., Haueter, C., Zoghbi, A., Harati, Y., Kwan, J. *et al.* (2008) The amyotrophic lateral sclerosis 8 protein VAPB is cleaved, secreted, and acts as a ligand for Eph receptors. *Cell*, **133**, 963–977.
8. Han, S.M., Tsuda, H., Yang, Y., Vibbert, J., Cottee, P., Lee, S.-J., Winek, J., Haueter, C., Bellen, H.J. and Miller, M.A. (2012) Secreted VAPB/ALS8 major sperm protein domains modulate mitochondrial localization and morphology via growth cone guidance receptors. *Dev. Cell*, **22**, 348–362.
9. Ratnaparkhi, A., Lawless, G.M., Schweizer, F.E., Golshani, P. and Jackson, G.R. (2008) A *Drosophila* model of ALS: human ALS-associated mutation in VAP33A suggests a dominant negative mechanism. *PLoS ONE*, **3**, e2334.
10. Kanekura, K., Nishimoto, I., Aiso, S. and Matsuoka, M. (2006) Characterization of amyotrophic lateral sclerosis-linked P56S mutation of vesicle-associated membrane protein-associated protein B (VAPB/ALS8). *J. Biol. Chem.*, **281**, 30223–30233.
11. Langou, K., Moumen, A., Pellegrino, C., Aebischer, J., Medina, I., Aebischer, P. and Raoul, C. (2010) AAV-mediated expression of wild-type and ALS-linked mutant VAPB selectively triggers death of motoneurons through a Ca²⁺-dependent ER-associated pathway. *J. Neurochem.*, **114**, 795–809.
12. Suzuki, H., Kanekura, K., Levine, T.P., Kohno, K., Olkkonen, V.M., Aiso, S. and Matsuoka, M. (2009) ALS-linked P56S-VAPB, an aggregated loss-of-function mutant of VAPB, predisposes motor neurons to ER stress-related death by inducing aggregation of co-expressed wild-type VAPB. *J. Neurochem.*, **108**, 973–985.
13. Gkogkas, C., Middleton, S., Kremer, A.M., Wardrope, C., Hannah, M., Gillingwater, T.H. and Skehel, P. (2008) VAPB interacts with and modulates the activity of ATF6. *Hum. Mol. Genet.*, **17**, 1517–1526.
14. Mórotz, G.M., De Vos, K.J., Vagnoni, A., Ackerley, S., Shaw, C.E. and Miller, C.C.J. (2012) Amyotrophic lateral sclerosis-associated mutant VAPBP56S perturbs calcium homeostasis to disrupt axonal transport of mitochondria. *Hum. Mol. Genet.*, **21**, 1979–1988.
15. Di Paolo, G. and De Camilli, P. (2006) Phosphoinositides in cell regulation and membrane dynamics. *Nature*, **443**, 651–657.
16. Guo, S., Stolz, L.E., Lemrow, S.M. and York, J.D. (1999) SAC1-like domains of yeast SAC1, INP52, and INP53 and of human synaptojanin encode polyphosphoinositide phosphatases. *J. Biol. Chem.*, **274**, 12990–12995.
17. Foti, M., Audhya, A. and Emr, S.D. (2001) Sac1 lipid phosphatase and Stt4 phosphatidylinositol 4-kinase regulate a pool of phosphatidylinositol

- 4-phosphate that functions in the control of the actin cytoskeleton and vacuole morphology. *Mol. Biol. Cell*, **12**, 2396–2411.
18. Brice, S.E., Alford, C.W. and Cowart, L.A. (2009) Modulation of sphingolipid metabolism by the phosphatidylinositol-4-phosphate phosphatase Sac1p through regulation of phosphatidylinositol in *Saccharomyces cerevisiae*. *J. Biol. Chem.*, **284**, 7588–7596.
 19. Wei, H.-C., Sanny, J., Shu, H., Baillie, D.L., Brill, J.A., Price, J.V. and Harden, N. (2003) The Sac1 lipid phosphatase regulates cell shape change and the JNK cascade during dorsal closure in *Drosophila*. *Curr. Biol.*, **13**, 1882–1887.
 20. Lee, S., Kim, S., Nahm, M., Kim, E., Kim, T.-I., Yoon, J.H. and Lee, S. (2011) The phosphoinositide phosphatase Sac1 is required for midline axon guidance. *Mol. Cell*, **32**, 477–482.
 21. Liu, Y., Boukhelifa, M., Tribble, E., Morin-Kensicki, E., Uetrecht, A., Bear, J.E. and Bankaitis, V.A. (2008) The Sac1 phosphoinositide phosphatase regulates Golgi membrane morphology and mitotic spindle organization in mammals. *Mol. Biol. Cell*, **19**, 3080–3096.
 22. Chow, C.Y., Landers, J.E., Bergren, S.K., Sapp, P.C., Grant, A.E., Jones, J.M., Everett, L., Lenk, G.M., McKenna-Yasek, D.M., Weisman, L.S. *et al.* (2009) Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. *Am. J. Hum. Genet.*, **84**, 85–88.
 23. Chow, C.Y., Zhang, Y., Dowling, J.J., Jin, N., Adamska, M., Shiga, K., Szigeti, K., Shy, M.E., Li, J., Zhang, X. *et al.* (2007) Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J. *Nature*, **448**, 68–72.
 24. Giot, L., Bader, J.S., Brouwer, C., Chaudhuri, A., Kuang, B., Li, Y., Hao, Y.L., Ooi, C.E., Godwin, B., Vitols, E. *et al.* (2003) A protein interaction map of *Drosophila melanogaster*. *Science*, **302**, 1727–1736.
 25. Roos, J., Hummel, T., Ng, N., Klämbt, C. and Davis, G.W. (2000) *Drosophila* Futsch regulates synaptic microtubule organization and is necessary for synaptic growth. *Neuron*, **26**, 371–382.
 26. Sherwood, N.T., Sun, Q., Xue, M., Zhang, B. and Zinn, K. (2004) *Drosophila* spastin regulates synaptic microtubule networks and is required for normal motor function. *PLoS Biol.*, **2**, e429.
 27. Wagh, D.A., Rasse, T.M., Asan, E., Hofbauer, A., Schwenkert, I., Dürbeck, H., Buchner, S., Dabauvalle, M.-C., Schmidt, M., Qin, G. *et al.* (2006) Bruchpilot, a protein with homology to ELKS/CAST, is required for structural integrity and function of synaptic active zones in *Drosophila*. *Neuron*, **49**, 833–844.
 28. Pielage, J., Bulat, V., Zuchero, J.B., Fetter, R.D. and Davis, G.W. (2011) Hts/Adducin controls synaptic elaboration and elimination. *Neuron*, **69**, 1114–1131.
 29. Wang, J., Gambhir, A., Hangyás-Mihályné, G., Murray, D., Golebiewska, U. and McLaughlin, S. (2002) Lateral sequestration of phosphatidylinositol 4,5-bisphosphate by the basic effector domain of myristoylated alanine-rich C kinase substrate is due to nonspecific electrostatic interactions. *J. Biol. Chem.*, **277**, 34401–34412.
 30. Pielage, J., Fetter, R.D. and Davis, G.W. (2006) A postsynaptic spectrin scaffold defines active zone size, spacing, and efficacy at the *Drosophila* neuromuscular junction. *J. Cell Biol.*, **175**, 491–503.
 31. Ikeda, Y., Dick, K.A., Weatherspoon, M.R., Gincel, D., Armbrust, K.R., Dalton, J.C., Stevanin, G., Dürr, A., Zühlke, C., Bürk, K. *et al.* (2006) Spectrin mutations cause spinocerebellar ataxia type 5. *Nat. Genet.*, **38**, 184–190.
 32. Wang, S., Yang, J., Tsai, A., Kuca, T., Sanny, J., Lee, J., Dong, K., Harden, N. and Krieger, C. (2011) *Drosophila* adducin regulates Dlg phosphorylation and targeting of Dlg to the synapse and epithelial membrane. *Dev. Biol.*, **357**, 392–403.
 33. Featherstone, D.E., Davis, W.S., Dubreuil, R.R. and Broadie, K. (2001) *Drosophila* alpha- and beta-spectrin mutations disrupt presynaptic neurotransmitter release. *J. Neurosci.*, **21**, 4215–4224.
 34. Ruiz-Canada, C., Ashley, J., Moeckel-Cole, S., Drier, E., Yin, J. and Budnik, V. (2004) New synaptic bouton formation is disrupted by misregulation of microtubule stability in aPKC mutants. *Neuron*, **42**, 567–580.
 35. Whitters, E.A., Cleves, A.E., McGee, T.P., Skinner, H.B. and Bankaitis, V.A. (1993) SAC1p is an integral membrane protein that influences the cellular requirement for phospholipid transfer protein function and inositol in yeast. *J. Cell Biol.*, **122**, 79–94.
 36. Nemoto, Y., Kearns, B.G., Wenk, M.R., Chen, H., Mori, K., Alb, J.G. Jr, De Camilli, P. and Bankaitis, V.A. (2000) Functional characterization of a mammalian Sac1 and mutants exhibiting substrate-specific defects in phosphoinositide phosphatase activity. *J. Biol. Chem.*, **275**, 34293–34305.
 37. Culi, J. and Mann, R.S. (2003) Boca, an endoplasmic reticulum protein required for wingless signaling and trafficking of LDL receptor family members in *Drosophila*. *Cell*, **112**, 343–354.
 38. Piao, H. and Mayinger, P. (2012) Growth and metabolic control of lipid signalling at the Golgi. *Biochem. Soc. Trans.*, **40**, 205–209.
 39. Stefan, C.J., Manford, A.G., Baird, D., Yamada-Hanff, J., Mao, Y. and Emr, S.D. (2011) Osh proteins regulate phosphoinositide metabolism at ER-plasma membrane contact sites. *Cell*, **144**, 389–401.
 40. Warrick, J.M., Chan, H.Y., Gray-Board, G.L., Chai, Y., Paulson, H.L. and Bonini, N.M. (1999) Suppression of polyglutamine-mediated neurodegeneration in *Drosophila* by the molecular chaperone HSP70. *Nat. Genet.*, **23**, 425–428.
 41. Yavari, A., Nagaraj, R., Owusu-Ansah, E., Folick, A., Ngo, K., Hillman, T., Call, G., Rohatgi, R., Scott, M.P. and Banerjee, U. (2010) Role of lipid metabolism in smoothened derepression in hedgehog signaling. *Dev. Cell*, **19**, 54–65.
 42. Panaretou, C., Domin, J., Cockcroft, S. and Waterfield, M.D. (1997) Characterization of p150, an adaptor protein for the human phosphatidylinositol (PtdIns) 3-kinase. Substrate presentation by phosphatidylinositol transfer protein to the p150.PtdIns 3-kinase complex. *J. Biol. Chem.*, **272**, 2477–2485.
 43. Jones, S.M., Alb, J.G. Jr, Phillips, S.E., Bankaitis, V.A. and Howell, K.E. (1998) A phosphatidylinositol 3-kinase and phosphatidylinositol transfer protein act synergistically in formation of constitutive transport vesicles from the trans-Golgi network. *J. Biol. Chem.*, **273**, 10349–10354.
 44. Kagiwada, S. and Hashimoto, M. (2007) The yeast VAP homolog Scs2p has a phosphoinositide-binding ability that is correlated with its activity. *Biochem. Biophys. Res. Commun.*, **364**, 870–876.
 45. Manford, A.G., Stefan, C.J., Yuan, H.L., Macgurn, J.A. and Emr, S.D. (2012) ER-to-plasma membrane tethering proteins regulate cell signaling and ER morphology. *Dev. Cell*, **23**, 1129–1140.
 46. Van Blitterswijk, M., Van Es, M.A., Koppers, M., Van Rheeën, W., Medic, J., Schelhaas, H.J., Van der Kooi, A.J., De Visser, M., Veldink, J.H. and Van den Berg, L.H. (2012) VAPB and C9orf72 mutations in 1 familial amyotrophic lateral sclerosis patient. *Neurobiol. Aging*, **33**, 2950.e1–2950.e4.
 47. Faulhammer, F., Kanjilal-Kolar, S., Knödler, A., Lo, J., Lee, Y., Konrad, G. and Mayinger, P. (2007) Growth control of Golgi phosphoinositides by reciprocal localization of sac1 lipid phosphatase and pik1 4-kinase. *Traffic*, **8**, 1554–1567.
 48. Blagoveshchenskaya, A., Cheong, F.Y., Rohde, H.M., Glover, G., Knödler, A., Nicolson, T., Boehmelt, G. and Mayinger, P. (2008) Integration of Golgi trafficking and growth factor signaling by the lipid phosphatase SAC1. *J. Cell Biol.*, **180**, 803–812.
 49. Kim, E.K. and Choi, E.-J. (2010) Pathological roles of MAPK signaling pathways in human diseases. *Biochim. Biophys. Acta*, **1802**, 396–405.
 50. Toulmay, A. and Prinz, W.A. (2011) Lipid transfer and signaling at organelle contact sites: the tip of the iceberg. *Curr. Opin. Cell Biol.*, **23**, 458–463.
 51. Hayashi, M., Raimondi, A., O'Toole, E., Paradise, S., Collesi, C., Cremona, O., Ferguson, S.M. and De Camilli, P. (2008) Cell- and stimulus-dependent heterogeneity of synaptic vesicle endocytic recycling mechanisms revealed by studies of dynamin 1-null neurons. *Proc. Natl Acad. Sci. USA*, **105**, 2175–2180.
 52. Suzuki, E. and Hirose, K. (1994) Immunolocalization of a *Drosophila* phosphatidylinositol transfer protein (rdgB) in normal and rdgA mutant photoreceptor cells with special reference to the subrhabdomeric cisternae. *J. Electron Microsc. (Tokyo)*, **43**, 183–189.
 53. Peretti, D., Dahan, N., Shimoni, E., Hirschberg, K. and Lev, S. (2008) Coordinated lipid transfer between the endoplasmic reticulum and the Golgi complex requires the VAP proteins and is essential for Golgi-mediated transport. *Mol. Biol. Cell*, **19**, 3871–3884.
 54. Rocha, N., Kuijl, C., Van der Kant, R., Janssen, L., Houben, D., Janssen, H., Zwart, W. and Neeffjes, J. (2009) Cholesterol sensor ORP1L contacts the ER protein VAP to control Rab7-RILP-p150 Glued and late endosome positioning. *J. Cell Biol.*, **185**, 1209–1225.
 55. De Vos, K.J., Mórotz, G.M., Stoica, R., Tudor, E.L., Lau, K.-F., Ackerley, S., Warley, A., Shaw, C.E. and Miller, C.C.J. (2012) VAPB interacts with the mitochondrial protein PTP1P51 to regulate calcium homeostasis. *Hum. Mol. Genet.*, **21**, 1299–1311.
 56. Audhya, A., Foti, M. and Emr, S.D. (2000) Distinct roles for the yeast phosphatidylinositol 4-kinases, Stt4p and Pik1p, in secretion, cell growth, and organelle membrane dynamics. *Mol. Biol. Cell*, **11**, 2673–2689.

57. Audhya, A. and Emr, S.D. (2002) Stt4 PI 4-kinase localizes to the plasma membrane and functions in the Pkc1-mediated MAP kinase cascade. *Dev. Cell*, **2**, 593–605.
58. Strahl, T., Hama, H., DeWald, D.B. and Thorner, J. (2005) Yeast phosphatidylinositol 4-kinase, Pik1, has essential roles at the Golgi and in the nucleus. *J. Cell Biol.*, **171**, 967–979.
59. Walch-Solimena, C. and Novick, P. (1999) The yeast phosphatidylinositol-4-OH kinase pik1 regulates secretion at the Golgi. *Nat. Cell Biol.*, **1**, 523–525.
60. Garrenton, L.S., Stefan, C.J., McMurray, M.A., Emr, S.D. and Thorner, J. (2010) Pheromone-induced anisotropy in yeast plasma membrane phosphatidylinositol-4,5-bisphosphate distribution is required for MAPK signaling. *Proc. Natl Acad. Sci. USA*, **107**, 11805–11810.
61. Cappell, S.D. and Dohlman, H.G. (2011) Selective regulation of MAP kinase signaling by an endomembrane phosphatidylinositol 4-kinase. *J. Biol. Chem.*, **286**, 14852–14860.
62. Yan, Y., Deneff, N., Tang, C. and Schüpbach, T. (2011) *Drosophila* PI4KIIIalpha is required in follicle cells for oocyte polarization and Hippo signaling. *Development*, **138**, 1697–1703.
63. Brill, J.A., Hime, G.R., Schärer-Schukasz, M. and Fuller, M.T. (2000) A phospholipid kinase regulates actin organization and intercellular bridge formation during germline cytokinesis. *Development*, **127**, 3855–3864.
64. Polevoy, G., Wei, H.-C., Wong, R., Szentpetery, Z., Kim, Y.J., Goldbach, P., Steinbach, S.K., Balla, T. and Brill, J.A. (2009) Dual roles for the *Drosophila* PI 4-kinase four wheel drive in localizing Rab11 during cytokinesis. *J. Cell Biol.*, **187**, 847–858.
65. Flanagan, C.A., Schnieders, E.A., Emerick, A.W., Kunisawa, R., Admon, A. and Thorner, J. (1993) Phosphatidylinositol 4-kinase: gene structure and requirement for yeast cell viability. *Science*, **262**, 1444–1448.
66. Yoshida, S., Ohya, Y., Goebel, M., Nakano, A. and Anraku, Y. (1994) A novel gene, STT4, encodes a phosphatidylinositol 4-kinase in the PKC1 protein kinase pathway of *Saccharomyces cerevisiae*. *J. Biol. Chem.*, **269**, 1166–1172.
67. Graham, T.R. and Burd, C.G. (2011) Coordination of Golgi functions by phosphatidylinositol 4-kinases. *Trends Cell Biol.*, **21**, 113–121.
68. Golub, T. and Caroni, P. (2005) PI(4,5)P2-dependent microdomain assemblies capture microtubules to promote and control leading edge motility. *J. Cell Biol.*, **169**, 151–165.
69. Klopfenstein, D.R. and Vale, R.D. (2004) The lipid binding pleckstrin homology domain in UNC-104 kinesin is necessary for synaptic vesicle transport in *Caenorhabditis elegans*. *Mol. Biol. Cell*, **15**, 3729–3739.
70. Nakatsu, F., Baskin, J.M., Chung, J., Tanner, L.B., Shui, G., Lee, S.Y., Pirruccello, M., Hao, M., Ingolia, N.T., Wenk, M.R. *et al.* (2012) PtdIns4P synthesis by PI4KIIIα at the plasma membrane and its impact on plasma membrane identity. *J. Cell Biol.*, **199**, 1003–1016.
71. Hammond, G.R.V., Fischer, M.J., Anderson, K.E., Holdich, J., Koteci, A., Balla, T. and Irvine, R.F. (2012) PI4P and PI(4,5)P2 are essential but independent lipid determinants of membrane identity. *Science*, **337**, 727–730.
72. Verstreken, P., Koh, T.-W., Schulze, K.L., Zhai, R.G., Hiesinger, P.R., Zhou, Y., Mehta, S.Q., Cao, Y., Roos, J. and Bellen, H.J. (2003) Synaptotagmin is recruited by endophilin to promote synaptic vesicle uncoating. *Neuron*, **40**, 733–748.
73. Breslow, D.K. and Weissman, J.S. (2010) Membranes in balance: mechanisms of sphingolipid homeostasis. *Mol. Cell*, **40**, 267–279.
74. Perry, R.J. and Ridgway, N.D. (2006) Oxysterol-binding protein and vesicle-associated membrane protein-associated protein are required for sterol-dependent activation of the ceramide transport protein. *Mol. Biol. Cell*, **17**, 2604–2616.
75. Hanada, K. (2006) Discovery of the molecular machinery CERT for endoplasmic reticulum-to-Golgi trafficking of ceramide. *Mol. Cell. Biochem.*, **286**, 23–31.
76. Raychaudhuri, S. and Prinz, W.A. (2010) The diverse functions of oxysterol-binding proteins. *Annu. Rev. Cell Dev. Biol.*, **26**, 157–177.
77. Trajkovic, K., Hsu, C., Chiantia, S., Rajendran, L., Wenzel, D., Wieland, F., Schwille, P., Brügger, B. and Simons, M. (2008) Ceramide triggers budding of exosome vesicles into multivesicular endosomes. *Science*, **319**, 1244–1247.
78. Zito, K., Parnas, D., Fetter, R.D., Isacoff, E.Y. and Goodman, C.S. (1999) Watching a synapse grow: noninvasive confocal imaging of synaptic growth in *Drosophila*. *Neuron*, **22**, 719–729.
79. Taha, T.A., Mullen, T.D. and Obeid, L.M. (2006) A house divided: ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death. *Biochim. Biophys. Acta*, **1758**, 2027–2036.
80. Wang, K., Yang, Z., Liu, X., Mao, K., Nair, U. and Klionsky, D.J. (2012) Phosphatidylinositol 4-kinases are required for autophagic membrane trafficking. *J. Biol. Chem.*, **287**, 37964–37972.
81. Kawano, M., Kumagai, K., Nishijima, M. and Hanada, K. (2006) Efficient trafficking of ceramide from the endoplasmic reticulum to the Golgi apparatus requires a VAMP-associated protein-interacting FFAT motif of CERT. *J. Biol. Chem.*, **281**, 30279–30288.
82. Bolte, S. and Cordelières, F.P. (2006) A guided tour into subcellular colocalization analysis in light microscopy. *J. Microsc.*, **224**, 213–232.